Table 3 Association of VEGF-C and VEGFR1 mRNA expression with basic patient and tumor characteristics.
| Â | Â | VEGF-C mRNA expression (Number = 305) | VEGFR1 mRNA expression (Number = 306) | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | Low (n= 229) Number (%) | High (n= 76) Number (%) | Pvalue | Low (n= 230) Number (%) | High (n= 76) Number (%) | Pvalue |
Age | <50 | 123 (53.9) | 29 (38.2) | 0.024 | 118 (51.5) | 35 (46.1) | 0.43 |
|  | ≥50 | 105 (46.1) | 47 (61.8) |  | 111 (48.5) | 41 (53.9) |  |
Treatment group | E-T-CMF | 113 (49.3) | 28 (36.8) | 0.064 | 110 (47.8) | 30 (39.5) | 0.23 |
| Â | E-CMF | 116 (50.7) | 48 (63.2) | Â | 120 (52.2) | 46 (60.5) | Â |
Menopausal status | Premenopausal | 130 (56.8) | 34 (44.7) | 0.084 | 128 (55.7) | 37 (48.7) | 0.35 |
| Â | Postmenopausal | 99 (43.2) | 42 (55.3) | Â | 102 (44.3) | 39 (51.3) | Â |
ER/PgR status | Negative | 34 (17.3) | 23 (37.7) | 0.001 | 37 (18.8) | 20 (33.3) | 0.021 |
| Â | Positive | 162 (82.7) | 38 (62.3) | Â | 160 (81.2) | 40 (66.7) | Â |
HER2 Statusa | Negative | 146 (78.5) | 31 (53.5) | <0.001 | 142 (76.3) | 35 (60.3) | 0.028 |
| Â | Positive | 40 (21.5) | 27 (46.6) | Â | 44 (23.7) | 23 (39.7) | Â |
Positive nodes | 0-3 | 61 (26.6) | 14 (18.4) | 0.17 | 61 (26.5) | 14 (18.4) | 0.17 |
|  | ≥4 | 168 (73.4) | 62 (81.6) |  | 169 (73.5) | 62 (81.6) |  |
Tumor size | ≤2 | 61 (26.6) | 30 (39.5) | 0.093 | 64 (27.8) | 27 (35.5) | 0.40 |
| Â | 2-5 | 127 (55.5) | 33 (43.4) | Â | 123 (53.5) | 38 (50.0) | Â |
| Â | >5 | 41 (17.9) | 13 (17.1) | Â | 43 (18.7) | 11 (14.5) | Â |
Histological grade | I-II | 113 (49.3) | 41 (53.9) | 0.51 | 118 (51.3) | 37 (48.7) | 0.79 |
| Â | III-IV | 116 (50.7) | 35 (46.1) | Â | 112 (48.7) | 39 (51.3) | Â |
Adjuvant HT | No | 17 (7.4) | 9 (11.8) | 0.24 | 20 (8.7) | 6 (7.9) | 0.99 |
| Â | Yes | 212 (92.6) | 67 (88.2) | Â | 210 (91.3) | 70 (92.1) | Â |
Adjuvant RT | No | 43 (18.9) | 11 (14.5) | 0.49 | 47 (20.5) | 7 (9.3) | 0.036 |
| Â | Yes | 184 (81.1) | 65 (85.5) | Â | 182 (79.5) | 68 (90.7) | Â |